- Home
- ETNB vs PAXS Comparison
ETNB vs PAXS Comparison
Compare ETNB & PAXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- PAXS
- Stock Information
- Founded
- ETNB 2018
- PAXS 2021
- Country
- ETNB United States
- PAXS United States
- Employees
- ETNB N/A
- PAXS N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- PAXS Investment Managers
- Sector
- ETNB Health Care
- PAXS Finance
- Exchange
- ETNB Nasdaq
- PAXS Nasdaq
- Market Cap
- ETNB 867.4M
- PAXS 703.9M
- IPO Year
- ETNB 2019
- PAXS N/A
- Fundamental
- Price
- ETNB $7.93
- PAXS $15.92
- Analyst Decision
- ETNB Buy
- PAXS
- Analyst Count
- ETNB 7
- PAXS 0
- Target Price
- ETNB $30.33
- PAXS N/A
- AVG Volume (30 Days)
- ETNB 901.8K
- PAXS 195.0K
- Earning Date
- ETNB 11-07-2024
- PAXS 01-01-0001
- Dividend Yield
- ETNB N/A
- PAXS 11.72%
- EPS Growth
- ETNB N/A
- PAXS N/A
- EPS
- ETNB N/A
- PAXS N/A
- Revenue
- ETNB N/A
- PAXS N/A
- Revenue This Year
- ETNB N/A
- PAXS N/A
- Revenue Next Year
- ETNB $133.30
- PAXS N/A
- P/E Ratio
- ETNB N/A
- PAXS N/A
- Revenue Growth
- ETNB N/A
- PAXS N/A
- 52 Week Low
- ETNB $7.00
- PAXS $12.57
- 52 Week High
- ETNB $16.63
- PAXS $15.93
- Technical
- Relative Strength Index (RSI)
- ETNB 42.09
- PAXS 44.09
- Support Level
- ETNB $9.00
- PAXS $15.58
- Resistance Level
- ETNB $10.01
- PAXS $16.18
- Average True Range (ATR)
- ETNB 0.80
- PAXS 0.25
- MACD
- ETNB -0.10
- PAXS 0.01
- Stochastic Oscillator
- ETNB 8.52
- PAXS 42.36
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.